Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.

Tytuł:
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Autorzy:
Agrawal M; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zhang X; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Brenner EJ; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ungaro RC; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kappelman MD; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Colombel JF; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2021 Nov 08; Vol. 15 (11), pp. 1877-1884.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2015- : Oxford : Oxford University Press
Original Publication: Amsterdam : Elsevier Science
MeSH Terms:
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*complications
Gastrointestinal Agents/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Adult ; Female ; Humans ; Male ; Middle Aged ; Registries ; SARS-CoV-2
References:
Gut. 2017 May;66(5):839-851. (PMID: 26893500)
N Engl J Med. 2013 Aug 22;369(8):699-710. (PMID: 23964932)
Gastroenterology. 2018 Aug;155(2):337-346.e10. (PMID: 29655835)
N Engl J Med. 2013 Aug 22;369(8):711-21. (PMID: 23964933)
Gastroenterology. 2020 Sep;159(3):1161-1163.e2. (PMID: 32422209)
Ann Rheum Dis. 2020 Jul;79(7):859-866. (PMID: 32471903)
Lancet. 2020 Jun 6;395(10239):1763-1770. (PMID: 32442528)
Gastroenterology. 2021 Jan;160(1):287-301.e20. (PMID: 32980345)
Ann Rheum Dis. 2021 Jul;80(7):930-942. (PMID: 33504483)
Inflamm Bowel Dis. 2021 Apr 15;27(5):662-666. (PMID: 32578843)
Gut. 2018 Jan;67(1):43-52. (PMID: 27802155)
Gut. 2021 Apr;70(4):725-732. (PMID: 33082265)
Gastroenterology. 2020 Oct;159(4):1541-1544.e2. (PMID: 32479824)
Inflamm Bowel Dis. 2020 May 12;26(6):797-808. (PMID: 32333601)
Sci Transl Med. 2018 Oct 3;10(461):. (PMID: 30282696)
Gastroenterology. 2020 Aug;159(2):481-491.e3. (PMID: 32425234)
Grant Information:
UL1TR002489 United States TR NCATS NIH HHS; UL1 TR002489 United States TR NCATS NIH HHS; K23 DK059311 United States DK NIDDK NIH HHS; T32DK007634 United States NH NIH HHS; 2003-04445 Helmsley Charitable Trust
Contributed Indexing:
Keywords: Crohn’s disease; Inflammatory bowel disease; coronavirus disease 2019; outcomes; ulcerative colitis; vedolizumab
Substance Nomenclature:
0 (Antibodies, Monoclonal, Humanized)
0 (Gastrointestinal Agents)
9RV78Q2002 (vedolizumab)
Entry Date(s):
Date Created: 20210422 Date Completed: 20211110 Latest Revision: 20220506
Update Code:
20240104
PubMed Central ID:
PMC8083188
DOI:
10.1093/ecco-jcc/jjab071
PMID:
33884425
Czasopismo naukowe
Background: The impact of immune-modifying therapies on outcomes of coronavirus disease 2019 [COVID-19] is variable. The purpose of this study was to determine the impact of vedolizumab [VDZ], a gut-selective anti-integrin, on COVID-19 outcomes in inflammatory bowel disease [IBD] patients.
Methods: Using data from the Surveillance of Coronavirus Under Research Exclusion for IBD [SECURE-IBD], an international registry of IBD patients with confirmed COVID-19, we studied the impact of VDZ on COVID-19 hospitalization and severe COVID-19 [intensive care unit stay, mechanical ventilation and/or death].
Results: Of 3647 adult patients on any IBD medication in the registry, 457 [12.5%] patients were on VDZ. On multivariable analyses using backward selection of covariates, VDZ use was not associated with hospitalization or severe COVID-19 when compared with patients on all other medications (adjusted odds ratio [aOR] 0.87; 95% confidence interval [CI] 0.71, 1.1 and aOR 0.95; 95% CI 0.53, 1.73, respectively). On comparing VDZ monotherapy to anti-tumour necrosis factor [anti-TNF] monotherapy, the odds for hospitalization, but not severe COVID-19, were higher [aOR CI 1.39; 95% CI 1.001, 1.90 and aOR 2.92; 95% CI 0.98, 8.71, respectively]. In an exploratory analysis, VDZ monotherapy, compared to anti-TNF monotherapy, was associated with new-onset gastrointestinal symptoms at the time of COVID-19, especially among patients whose IBD was in remission.
Conclusions: COVID-19 outcomes among IBD patients on VDZ are comparable to those on all other therapies. Hospitalization, but not severe COVID-19, is more likely with VDZ monotherapy than with anti-TNF monotherapy. Overall, VDZ appears to be safe in IBD patients with COVID-19.
(© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies